Influence of C C R5 δ32 polymorphism on multiple sclerosis susceptibility and disease course

Abstract

The C C R5 chemokine receptor has been implicated in the patho genesis of multiple sclerosis (MS). We carried out an allelic association study using a deletion polymorphism in the coding region of the C C R5 gene in 331 relapsing-remitting (RR) and secondary progressive (SP) MS patients, 108 primary progressive (PP) MS patients and 230 healthy controls. O f the 331 RR and SPMS patients, 172 were recruited from specialist clinics and 159 from a population survey. Disease severity was assessed clinically using the Expanded Disability Status Scale (EDSS) and used to calculate a progression index for each patient (defined as EDSS divided by duration of disease). No significant difference in distribution of the C C R5 d32 allele was observed between the 331 RR/SPMS patients and controls, between the 108 PPMS patients and controls or between the PPMS and RR/SPMS groups. Furthermore, no differences in rate of disease progression were detected between carriers and noncarriers of the d32 allele. In the population-based group of RR/SPMS patients, carriage of the C C R5 d32 polymorphism was associated with a lower age at disease onset (mean age 26.562 versus 31.065 years, P =0.003). However, no significant differences in age of onset were present in the PPMS group or in a second RRMS population. These results suggest that the C C R5 d32 polymorphism is not a major determinant of susceptibility to develop MS in the population under study, and conflict with a previously reported association between C C R5 d32 carriage and a better prognosis.

Keywords

autoimmunity C C R5 chemokine receptors chemokines human multiple sclerosis receptors

Get full access to this article

View all access options for this article.

References

McDonnell GV , Hawkins SA. An epidemiologic study of multiple sclerosis in Northern Ireland . Neurology 1998; 50: 423-428 .

Sadovnick AD , Armstrong H , Rice GPA , Bulman D , Hashimoto L , Paty DW et al. A population-based study of multiple sclerosis in twins: update . Ann Neurol. 1993; 33: 281-285 .

Sawcer S , Jones HB , Feakes R , Gray J , Smaldon N , Chataway J et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 . Nat Genet 1996; 13: 464-468 .

The Multiple Sclerosis Genetics Group . A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex . Nat Genet 1996; 13: 469-471 .

Ebers GC , Kukay K , Bulman DE , Sadovnick AD , Rice G et al. A full genome search in multiple sclerosis . Nat Genet 1996; 13: 472-476 .

McDonnell GV , Mawhinney H , Graham CA , Hawkins SA , Middleton D. A study of the HLA DR region in clinical subgroups of multiple sclerosis and its influence on prognosis . J Neurol Sci 1999; 165: 77-83 .

Cullen CG , Middleton D , Savage DA , Hawkins S. HLA-DR and-DQ genotyping in multiple sclerosis patients in Northern Ireland . Hum Immunol 1991; 30: 1-6 .

Mahad DJ , Howell SJ , Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis . J Neurol Neurosurg Psychiatry 2002; 72: 498-502 .

Miyagishi R , Kikuchi S , Fukazawa T , Tashiro K. Macrophage inflammatory protein-1a in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory diseases . J Neurol Sci 1995; 129: 223-227 .

10.

Sørensen TL , Tani M , Jensen J , Pierce V , Lucchinetti C , Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients . J Clin Invest 1999; 103: 807-815 .

11.

Simpson JE , Newcombe J , Cuzner ML , Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other b-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions . J Neuroimmunol 1998; 84: 238-249 .

12.

Balashov KE , Rottman JB , Weiner HL , Hancock WW. CCR5+and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1a and IP-10 are expressed in demyelinating brain lesions . Proc Natl Acad Sci USA 1999; 96: 6873-6878 .

13.

Zang YCQ , Samanta AK , Halder JB , Hong J , Tejada-Simon MV , Rivera VM et al. Aberrant T cell migration toward RANTES and MIP-1a in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5 . Brain 2000; 123: 1874-1882 .

14.

Dai Y , Xu C , Holmberg M , Oturai A , Fredrikson S , Sanberg-Wollheim M et al. Linkage analysis suggests region of a importance for multiple sclerosis in 3 p14-13 . Revue Neurol 2000; 156: P123-P123 .

15.

Bennetts BH , Teutsch SM , Buhler MM , Heard RNS , Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis . Hum Immunol 1997; 58: 52-59 .

16.

Chataway J , Sawcer S , Feakes R , Coraddu F , Broadley S , Gray J et al. More evidence that founder effects exist in the European population . Eur J Hum Genet 1997; 7: 623-624 .

17.

Sellebjerg F , Madsen HO , Jensen CV , Jensen J , Garred J. CCR5 d32, matrix metalloproteinase-9 and disease activity in multiple sclerosis . J Neuroimmunol 2000; 102: 98-106 .

18.

Multiple Sclerosis Genetics Group . CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis . Immunogenetics 2000; 51: 281-288 .

19.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 1983; 33: 144-152 .

20.

Jeanpierre M. A rapid method for the purification of DNA from blood . Nucleic Acids Res 1987; 15: 961-961 .

21.

Benkirane M , Jin D-Y , Chun RF , Koup RA , Jeang K-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5d32 . J Biol Chem 1997; 272: 30603-30606 .

22.

Baggiolini M. Chemokines and leukocyte traffic . Nature 1998; 392: 565-568 .

23.

Giovannoni G , Kieseier B , Hartung HP. Correlating immuno-logical and magnetic resonance imaging markers of disease activity in multiple sclerosis . J Neurol Neurosurg Psychiatry 1998; 64 Suppl: S31-S36 .